N1.ID

The N.1 Infectious Diseases Programme

The world is currently being confronted by unprecedented challenges with COVID-19. One of the most prevalent issues brought on by the COVID-19 pandemic has been the identification of actionable and optimised therapies towards this aggressive pathogen. At the onset of the COVID-19 emergence, N.1 initiated multiple programmes and collaborations to overcome this barrier. There are currently a number of active trials to pinpoint interventions that may result in positive patient outcomes. However, there is also a need to truly optimise the treatment arsenal by rapidly determining the right therapies and right dosages that will indeed confer benefit to COVID-19 patients. This is where the N.1 suite of AI/digital medicine portfolio comes in. We have a track record of clinically validating our drug development and administration approaches. These are different aspects of bringing optimised therapy to patients, and both must be considered. Read our recent paper and check out our recent podcast to learn more.

Beyond the development of therapeutic strategies against COVID-19, our team has committed itself to build a standing programme to target a broader range of infectious diseases that have continued to affect millions across the world. By harnessing our in-house AI/Digital Medicine platforms, this programme will target COVID-19, cement our preparedness for future epidemics/pandemics, and address chronic infectious that continue to affect millions of patients each year. Our efforts have already led to life-saving outcomes. We’re calling this programme: N1.ID

//

N1.ID/Project IDentif.AI

In January 2020, we initiated Project IDentif.AI (Optimising infectious disease therapy with AI) to validate our AI platforms to rapidly and simultaneously pinpoint the best drugs and doses for ID drug development (within days). This project has involved expertise from our N.1 AI/digital medicine teams as well as leading experts in global health security and surveillance, healthcare economics, analytics, and beyond in order to assess our downstream abilities to deploy IDentif.AI under austere economic and logistical conditions. Our first peer-reviewed publication is due to be released shortly (estimated early-April 2020). Please stay tuned for more information on the release date and associated resources and events. Continued development on the Project IDentif.AI platform is ongoing.

//

N1.ID/HIV

In March 2020, amidst the COVID-19 outbreak, the emergence of drug shortages for HIV, a disease that afflicts 37.9 million and caused ~770,000 deaths worldwide in 2018 (UNAIDS) were reported (Link). At the same time, high-dose treatment with certain HIV therapies has previously led to long-term complications, including kidney failure. Harnessing CURATE.AI as a potential solution, N.1 recently participated in a human study (10 patients, see figure) that demonstrated an ~33% reduction in the dosage of one of these therapies while maintaining undetectable viral loads and zero risk of transmission. See the paper Link.

//

N1.ID/TB

On TB Day on March 24th, a powerful TB combination therapy based on our technology platforms, was announced. This combination has cut patient treatment time in half, developed with an orders-of-magnitude reduction in cost, and taken to clinic years faster. These are unprecedented outcomes.

Worldwide patent rates will not be pursued for this combination so that it can be broadly used by the world.

Drug adherence in TB is challenging. Patients need the best possible chance of finishing their medication. Our technology platforms further this aim and can give more people a chance to survive.

TB kills more people annually than any other single pathogen, taking the lives of 1.6 million people each year, or 4000 every day. Over the next year, clinical data will be released for the benefit of the global ID community.